Expression and Promoter-Hyper Methylation Analysis of MGMT Gene in Patients with Pterygium

Document Type : Original Article


1 Departement of Biology, University of Sistan and Baluchestan, Zahedan, Iran

2 Department of Ophthalmology, Al-Zahra Eye Hospital, Zahedan University of Medical Sciences, Zahedan ,Iran

3 Department of Ophthalmology, Al-Zahra Eye Hospital, Zahedan University of Medical Sciences , Zahedan ,Iran


1)Background: Pterygium is a benign legion and is observed as aggressive growth of
conjunctiva fibro-vascular tissue on the cornea. The alkylating agents are observed as
considerable threats for human health because alkylated lesions lead to cytotoxic,
teratogenic and cancerizing effects. MGMT is one of the repair proteins of DNA which
repairs the alkylated lesions. Expression and activity of MGMT is controlled by
epigenetic mechanisms such as DNA methylation in the promoter regions like
transcription factors which are connected to MGMT promoter and lead to positive or
negative induction of that activity, protein-protein interactions, and negative regulation.
2)Materials and methods: In order to study methylation, DNA samples of 43 patients
and 40 healthy individuals were extracted, bisulfited and then were studied. Also in
order to study the expression, RNA was extracted from 15 other patients and 15 other
healthy individuals; and then, the technique of Real-time PCR was used. 3)Results:
analysis of promoter methylation of MGTM gene showed that there is no significant
relationship in the situation of promoter methylation between the patients and control
individuals (P value = 0.43; 95%Cl = 0.66-2.40; OR = 1.52). However, analysis of
MGMT gene expression showed significant difference between the patients and control
individuals (Mean ± SD: 1.25 ± 0.10 and 1.52 ± 2.91, respectively; P value = 0.009). 4)Conclusion: since there are no significant changes of promoter methylation of MGMT
gene, there seems to be other unknown procedures that regulate this gene’s expression
levels. In this respect, expression of MGMT gene in the pterygium increases through
unknown procedures. In order to approve this data, further studies are suggested in more
populations with bigger sample sizes by the use of advanced molecular techniques.


Esteller, M. and J. G. J. O. Herman (2004). "Generating mutations but providing chemosensitivity: the role of O 6-methylguanine DNA methyltransferase in human cancer."  23(1): 1.
Fu, D., et al. (2012). "Balancing repair and tolerance of DNA damage caused by alkylating agents."  12(2): 104.
Koranyi, G. (2010). The cut and paste technique fibrin tissue adhesive in pterygium surgery, Institutionen för klinisk neurovetenskap/Department of Clinical Neuroscience.
Liu, T., et al. (2013). "Progress in the pathogenesis of pterygium."  38(12): 1191-1197.
Liu, Y., et al. (2017). "mTORC1 regulates apoptosis and cell proliferation in pterygium via targeting autophagy and FGFR3."  7(1): 7339.
Ozturk, B., et al. (2017). "K-ras oncogene mutation in pterygium."  31(3): 491.
Tradjutrisno, N. J. U. M. (2016). "Pterygium: degeneration, exuberant wound healing or benign neoplasm?"  28(3): 179-187.
Wick, W., et al. (2014). "MGMT testing—the challenges for biomarker-based glioma treatment."  10(7): 372.
Wickström, M., et al. (2015). "Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance."  6: 8904.
Xu, K., et al. (2013). "Increased importin 13 activity is associated with the pathogenesis of pterygium."  19: 604.
Liu al.(2017). “Identification of pterygium-related mRNA expression profiling by microarray analysis.” 31(12):1733.
Volume 1, Issue 2
April 2019
Pages 1-8
  • Receive Date: 14 January 2019
  • Revise Date: 16 April 2019
  • Accept Date: 22 April 2019
  • First Publish Date: 22 April 2019